Clin Chest Med. 2021 Jun;42(2):275-285. doi: 10.1016/j.ccm.2021.03.004.
ABSTRACT
Progress in the past 2 decades has led to widespread use of 2 medications to slow loss of lung function in patients with pulmonary fibrosis. Treatment of individual patients with currently available pharmacotherapies can be limited by side effects, and neither drug has a consistent effect on patient symptoms or function. Several promising new pharmacotherapies are under development. Comprehensive management of pulmonary fibrosis hinges on shared decision making. Patient and caregiver education, and early identification and management of symptoms and comorbidities, can help improve quality of life.
PMID:34024403 | DOI:10.1016/j.ccm.2021.03.004